StockData
AbCellera Biologics Inc. logo

AbCellera Biologics Inc. (ABCL) company profile

ABCLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30155% above fair value
$11.49−0.13 (-1.12%)

Close on Nov 13, 2026Market cap $3.52BP/E –Yield –

About AbCellera Biologics

Pharmaceutical Preparations, SIC 2834

AbCellera is a clinical-stage biotechnology company that discovers and develops antibody medicines for disease areas with high unmet medical needs. The company utilizes a vertically integrated technology platform that combines computational tools and laboratory research to discover antibodies from natural immune responses. Its internal pipeline features clinical-stage drug candidates, including ABCL635 for menopausal vasomotor symptoms and ABCL575 for atopic dermatitis, as well as preclinical candidates in autoimmunity and oncology. Additionally, the company collaborates with global biopharmaceutical and biotechnology partners to discover and advance therapeutic programs.

The company employs 562 full-time staff members representing more than 42 nationalities across Canada, Australia, and the United States. Its largest facilities are located in Vancouver, Canada, and Sydney, Australia. In Vancouver, the company maintains a 130,000-square-foot clinical manufacturing facility to support early-stage clinical trial supplies and platform operations. AbCellera has initiated more than 100 partner programs, with 19 molecules reaching clinical trials.

Summary of the business section of AbCellera Biologics's latest annual report, written by StockData.

Company profile

Company

Legal name
AbCellera Biologics Inc.
Founded
2012
Headquarters
Vancouver, A1
Address
150 W 4th Avenue V5Y 1G6
Phone
(604) 559-9005
Employees
562, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
A1
Fiscal year ends
December 31
Auditor
KPMG LLPChartered Professional Accountants, Vancouver, Canada

Stock & identifiers

Ticker
ABCL
Exchange
Nasdaq
IPO date
Dec 14, 2020
Shares outstanding
307M, Aug 3, 2026
Public float
$789.23M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1703057
CUSIP
00288U106
ISIN
CA00288U1066
FIGI
BBG00LLW2MF2
Share class FIGI
BBG00LLW2MH0
LEI
9845000861BC95FF9F73
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Carl L. G. HansenChief Executive Officer, Director56,984,009
Veronique LecaultChief Technology Officer, Director9,340,044
Andrew BoothChief Financial Officer622,359
Tryn StimartChief Legal Officer500
Michael R. HaydenDirector1,491,642
John S. MontalbanoDirector256,000
Victor SandorDirector–
Lynn SeelyDirector–
Stephen QuakeDirector1,100,436
Andrew LoDirector86,938

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.29M$7.27M$2.68M$9$120
FY2024$8.25M-$347.46K$3.25M$7$91
FY2023$714.94K-$14.62M$664.28K$14$92
FY2022$8.80M-$12.52M$4.71M$25$89
FY2021$9.12M-$122.89M$4.07M$36$99
FY2020$16.96M$196.56M$5.19M$68$101

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Carl L.G. Hansen, Ph.D.
Chief Executive Officer
$550.00K$357.91K$5.36M$23.24K$6.29M-24%
Andrew Booth
Chief Financial Officer
$485.00K$218.57K$2.66M$23.24K$3.38M-1%
Véronique Lecault, Ph.D.
Chief Technology Officer
$454.00K$204.40K$1.63M$23.24K$2.32M-32%
Tryn Stimart
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary, and Privacy Officer
$470.00K$211.13K$1.63M$28.15K$2.34M-19%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 14, 2020
Offer price
$20.00
Securities offered
24,150,000
Gross proceeds
$483.00M
Exchange
Nasdaq
First trading day
Dec 11, 2020
First-day close
$58.90+194.5%
Lock-up ends (est.)
Jun 9, 2021

“The initial public offering price per share of our common shares is $20.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 562 full-time employees in Canada, Australia, and the United States, representing over 42 nationalities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?